A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms SERENITY
- Sponsors Eli Lilly and Company
- 17 Oct 2023 Results assessing efficacy and safety of mirikizumab extending to W104, presented at the 31st United European Gastroenterology Week.
- 17 Oct 2023 Results assessing IBDQ scores through Week 104, presented at the 31st United European Gastroenterology Week.
- 17 Oct 2023 Results assessing potential relationship between early histologic and endoscopic responses on long term clinical outcomes after 2 years of mirikizumab treatment, presented at the 31st United European Gastroenterology Week.